Have a feature idea you'd love to see implemented?
Let us know!
EXAS Exact Sciences Corp
Price (delayed)
$57.55
Market cap
$10.65B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.17
Enterprise value
$12.82B
Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer. Exact Sciences Corp. launched Cologuard in 2014, the first
Highlights
EXAS's revenue is up by 12% year-on-year and by 3.1% since the previous quarter
EXAS's gross profit is up by 11% year-on-year and by 2.8% since the previous quarter
Exact Sciences's EPS has increased by 26% YoY but it has decreased by 22% from the previous quarter
The company's net income rose by 24% YoY but it fell by 22% QoQ
The company's quick ratio fell by 9% YoY
The company's debt rose by 8% YoY
Key stats
What are the main financial stats of EXAS
Market
Valuations
Earnings
Shares outstanding
185.08M
Market cap
$10.65B
Enterprise value
$12.82B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.31
Price to sales (P/S)
3.95
EV/EBIT
N/A
EV/EBITDA
220.15
EV/Sales
4.76
Revenue
$2.69B
Gross profit
$1.96B
Net income
-$214.04M
EBIT
-$185.27M
EBITDA
$58.24M
Free cash flow
$98.43M
Per share
Balance sheet
Liquidity
EPS
-$1.17
EPS diluted
-$1.17
Free cash flow per share
$0.53
Book value per share
$17.38
Revenue per share
$14.57
TBVPS
$13.62
Total assets
$6.75B
Total liabilities
$3.54B
Debt
$2.76B
Equity
$3.21B
Working capital
$809.46M
Debt to equity
0.86
Current ratio
2.12
Quick ratio
1.78
Net debt/EBITDA
37.26
Margins
Efficiency
Dividend
EBITDA margin
2.2%
Gross margin
73%
Net margin
-7.9%
Operating margin
-8.9%
Return on assets
-3.3%
Return on equity
-6.8%
Return on invested capital
-4.8%
Return on capital employed
-3.1%
Return on sales
-6.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
EXAS stock price
How has the Exact Sciences stock price performed over time
Intraday
0.12%
1 week
-3.11%
1 month
-6.71%
1 year
-23.96%
YTD
-22.21%
QTD
-15.52%
Financial performance
How have Exact Sciences's revenue and profit performed over time
Revenue
$2.69B
Gross profit
$1.96B
Operating income
-$240.19M
Net income
-$214.04M
Gross margin
73%
Net margin
-7.9%
The company's net margin rose by 32% YoY but it fell by 18% QoQ
The company's net income rose by 24% YoY but it fell by 22% QoQ
The operating income has declined by 24% since the previous quarter but it has increased by 10% year-on-year
The operating margin has declined by 20% since the previous quarter but it has increased by 20% year-on-year
Growth
What is Exact Sciences's growth rate over time
Valuation
What is Exact Sciences stock price valuation
P/E
N/A
P/B
3.31
P/S
3.95
EV/EBIT
N/A
EV/EBITDA
220.15
EV/Sales
4.76
Exact Sciences's EPS has increased by 26% YoY but it has decreased by 22% from the previous quarter
The stock's price to book (P/B) is 25% less than its 5-year quarterly average of 4.4 and 11% less than its last 4 quarters average of 3.7
The company's equity rose by 2.9% YoY
EXAS's price to sales (P/S) is 49% less than its 5-year quarterly average of 7.8 and 12% less than its last 4 quarters average of 4.5
EXAS's revenue is up by 12% year-on-year and by 3.1% since the previous quarter
Efficiency
How efficient is Exact Sciences business performance
Exact Sciences's ROS has increased by 37% YoY but it has decreased by 21% from the previous quarter
The company's return on invested capital rose by 33% YoY but it fell by 20% QoQ
EXAS's return on assets is up by 27% year-on-year but it is down by 22% since the previous quarter
The ROE has grown by 26% YoY but it has contracted by 21% from the previous quarter
Dividends
What is EXAS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for EXAS.
Financial health
How did Exact Sciences financials performed over time
The total assets is 91% more than the total liabilities
EXAS's current ratio is down by 12% YoY and by 2.3% QoQ
The company's quick ratio fell by 9% YoY
The company's debt is 14% lower than its equity
The company's debt rose by 8% YoY
EXAS's debt to equity is up by 4.9% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.